NORWELL, Mass.--(BUSINESS WIRE)--Hocoma, a global medical technology company focused on robotic rehabilitation, is celebrating more than 17 successful years and over 2,500 devices sold - more than any other company in the segment of Neurorehabilitation, such as treatment for Stroke, Spinal Cord Injury and Traumatic Brain Injury.
“We are excited so many medical facilities around the globe have put their faith in us”, said Executive Vice President Frank Menzler. Patients in 74 countries around the world rely on Hocoma’s solutions to improve the efficiency and outcomes of their rehabilitation therapy. In the United States, Hocoma works with almost all of the top Rehabilitation Hospitals.
“Neurological disorders afflict thousands of people each year and Hocoma’s Total Solution Portfolio can help these patients recover faster and with better long-term outcomes” Menzler added. “Other than larger Hospitals increasingly smaller outpatient clinics install these devices, not only because of the clinical benefits seen but also because of increased patient satisfaction and patient demand.”
For more information, please contact us at 877-944-2200 or info.us@hocoma.com
Press images
https://www.hocoma.com/media-center/media-images/
About Hocoma
A successful therapy begins in patients’ heads. In the firm belief that – step by step – they can reach their goals and regain quality of life.
This is what we work for at the Swiss Medtech company Hocoma. With technologies and ideas that look at functional movement therapy from a completely different angle. Because they enable independent exercises and create maximum motivation. Because they challenge people to take courage and support their hopes with personal achievements.
We are committed to creating the ideal therapy. Our awarded robotic and sensor-based devices offer solutions for intensive gait therapy (Lokomat®, Andago®), functional therapy of the upper extremities (Armeo®), robotic mobilization and functional electrical stimulation in early rehabilitation (Erigo®) as well as functional movement therapy within low back pain treatment (Valedo® Therapy Concept) at home and at the clinic. They are the result of intensive research, consistent development and continuous exchange with patients, therapists and partners in research and science.
Those who see to break new grounds need to stay open to exceptional ideas. They have the potential of being exceptionally effective. This guiding principle by Hocoma founder and CEO Dr. Gery Colombo has accompanied us since our start in 2000 and is still lived and implemented by our dedicated employees around the world. At the headquarters in Volketswil near Zurich (Switzerland) and the subsidiaries in the USA, Singapore, Chile and Slovenia we achieved a turnover of approximately 30 million CHF in 2016.
Hocoma AG
Mike Fuhrmann, +41 43 444 23 65
Chief Creative Officer
media@hocoma.com
Fax: +41 43 444 22 01
www.hocoma.com
